Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
17.22
USDSponsored
-0.51
-2.88%
Nov 19, 15:59 UTC -5
Closed
After-Market
17.02
-0.20
-1.13%
Ultragenyx Pharmaceutical Inc. (RARE) Earnings
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 21 of 44 last estimates.
48%
Next Report
Date of Next Report
Feb 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$228.28M
/-$0.51
Implied change from Q3 26 (Revenue/ EPS)
+31.96%
/-55.65%
Implied change from Q4 25 (Revenue/ EPS)
+10.28%
/-60.47%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On Nov 03, 2026, RARE reported earnings of -1.15 USD per share (EPS) for Q3 26, missing the estimate of -1.13 USD, resulting in a -1.83% surprise. Revenue reached 173.00 million, compared to an expected 186.78 million, with a -7.38% difference. The market reacted with a +3.19% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.51 USD, with revenue projected to reach 228.28 million USD, implying an decrease of -55.65% EPS, and increase of 31.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%

AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%

Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%

CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%

Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-Actual
-$0.34
Surprise
-
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.15, missing estimates by -1.83%, and revenue of $173.00M, -7.38% below expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q3 2026 earnings?
The stock price moved up 3.19%, changed from $16.63 before the earnings release to $17.16 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for Feb 10, 2027.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on --
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$0.51 and revenue of $228.28M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.